» Articles » PMID: 7943542

Fatal Neurotoxicity of Arteether and Artemether

Overview
Specialty Tropical Medicine
Date 1994 Sep 1
PMID 7943542
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Artemisinin (qinghaosu) and several derivatives have been developed and are in use as antimalarial drugs but scant information is available regarding animal or human toxicity. Following a eight-day, multiple-dose, pharmacokinetic study of arteether (AE) (10 mg/kg/day [n = 6] and 20 mg/kg/day [n = 6]) in dogs, all high-dose animals displayed a progressive syndrome of clinical neurologic defects with progressive cardiorespiratory collapse and death in five of six animals. Neurologic findings included gait disturbances, loss of spinal and pain response reflexes, and prominent loss of brain stem and eye reflexes. Animals had prolongation of QT interval corrected for rate (QTc) on electrocardiograms (ECGs) with bizarre ST-T segment changes. Prominent neuropathic lesions were noted to be primarily limited to the pons and medulla. Similar lesions with dose-related severity were noted in eight other dogs studied in a second study with intramuscular (IM) administration of AE in sesame oil during a 28-day, dose-ranging study using 5, 10, 15, and 20 mg/kg/day. Injury, graded by a pathologist blinded to the dose group, showed a dose-related, region-specific injury in all animals that was most pronounced in the pons. Further studies in Sprague-Dawley rats using IM administration of AE and artemether (AM) at a dose of 12.5-50 mg/kg/day for 28 days confirmed the onset of a clinical neurologic syndrome with dose-related changes in body weight, activity, and seizure-like activity, stereotypic movement disorders, and ECG changes.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Recent Advancement in Drug Development for Treating Malaria using Herbal Medicine and Nanotechnological Approach.

Bhargava S, Deshmukh R, Dewangan H Curr Pharm Des. 2024; 31(3):203-218.

PMID: 39279710 DOI: 10.2174/0113816128321468240828103439.


Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria.

Gujjari L, Kalani H, Pindiprolu S, Arakareddy B, Yadagiri G Parasite Epidemiol Control. 2022; 17:e00244.

PMID: 35243049 PMC: 8866151. DOI: 10.1016/j.parepi.2022.e00244.


Parenteral artemisinins are associated with reduced mortality and neurologic deficits and improved long-term behavioral outcomes in children with severe malaria.

Conroy A, Opoka R, Bangirana P, Namazzi R, Okullo A, Georgieff M BMC Med. 2021; 19(1):168.

PMID: 34315456 PMC: 8317420. DOI: 10.1186/s12916-021-02033-1.


Structure-Activity Relationships of the Antimalarial Agent Artemisinin 10. Synthesis and Antimalarial Activity of Enantiomers of -5β-Hydroxy-d-Secoartemisinin and Analogs: Implications Regarding the Mechanism of Action.

Jahan M, Leon F, Fronczek F, Elokely K, Rimoldi J, Khan S Molecules. 2021; 26(14).

PMID: 34299438 PMC: 8304634. DOI: 10.3390/molecules26144163.


Longitudinal study based on a safety registry for malaria patients treated with artenimol-piperaquine in six European countries.

Vignier N, Bouchaud O, Angheben A, Bottieau E, Calleri G, Salas-Coronas J Malar J. 2021; 20(1):214.

PMID: 33964945 PMC: 8105939. DOI: 10.1186/s12936-021-03750-x.